BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25355421)

  • 21. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMARCA4 regulates gene expression and higher-order chromatin structure in proliferating mammary epithelial cells.
    Barutcu AR; Lajoie BR; Fritz AJ; McCord RP; Nickerson JA; van Wijnen AJ; Lian JB; Stein JL; Dekker J; Stein GS; Imbalzano AN
    Genome Res; 2016 Sep; 26(9):1188-201. PubMed ID: 27435934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
    Tian Y; Xu L; Li X; Li H; Zhao M
    Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
    Romero OA; Torres-Diz M; Pros E; Savola S; Gomez A; Moran S; Saez C; Iwakawa R; Villanueva A; Montuenga LM; Kohno T; Yokota J; Sanchez-Cespedes M
    Cancer Discov; 2014 Mar; 4(3):292-303. PubMed ID: 24362264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling.
    Yao B; Gui T; Zeng X; Deng Y; Wang Z; Wang Y; Yang D; Li Q; Xu P; Hu R; Li X; Chen B; Wang J; Zen K; Li H; Davis MJ; Herold MJ; Pan HF; Jiang ZW; Huang DCS; Liu M; Ju J; Zhao Q
    Genome Med; 2021 Apr; 13(1):58. PubMed ID: 33853662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.
    Shorstova T; Marques M; Su J; Johnston J; Kleinman CL; Hamel N; Huang S; Alaoui-Jamali MA; Foulkes WD; Witcher M
    Cancer Res; 2019 May; 79(10):2761-2774. PubMed ID: 30877105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of BRG1 silencing in primary cancers.
    Marquez-Vilendrer SB; Thompson K; Lu L; Reisman D
    Oncotarget; 2016 Aug; 7(35):56153-56169. PubMed ID: 27486753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial Inactivation of the Chromatin Remodelers SMARCA2 and SMARCA4 in Virus-Infected Cells by Caspase-Mediated Cleavage.
    Dudek AH; Pfaff F; Bolte H; Waguia Kontchou C; Schwemmle M
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29848589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
    Reichl KD; Lee ECY; Gopalsamy A
    Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
    Fernando TM; Piskol R; Bainer R; Sokol ES; Trabucco SE; Zhang Q; Trinh H; Maund S; Kschonsak M; Chaudhuri S; Modrusan Z; Januario T; Yauch RL
    Nat Commun; 2020 Nov; 11(1):5551. PubMed ID: 33144586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4.
    Schramedei K; Mörbt N; Pfeifer G; Läuter J; Rosolowski M; Tomm JM; von Bergen M; Horn F; Brocke-Heidrich K
    Oncogene; 2011 Jun; 30(26):2975-85. PubMed ID: 21317927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiRNA-Mediated Regulation of the SWI/SNF Chromatin Remodeling Complex Controls Pluripotency and Endodermal Differentiation in Human ESCs.
    Wade SL; Langer LF; Ward JM; Archer TK
    Stem Cells; 2015 Oct; 33(10):2925-35. PubMed ID: 26119756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.
    Kunimasa K; Nakamura H; Sakai K; Tamiya M; Kimura M; Inoue T; Nishino K; Kuhara H; Nakatsuka SI; Nishio K; Imamura F; Kumagai T
    Lung Cancer; 2019 Jun; 132():59-64. PubMed ID: 31097095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SWI/SNF complexes are required for full activation of the DNA-damage response.
    Smith-Roe SL; Nakamura J; Holley D; Chastain PD; Rosson GB; Simpson DA; Ridpath JR; Kaufman DG; Kaufmann WK; Bultman SJ
    Oncotarget; 2015 Jan; 6(2):732-45. PubMed ID: 25544751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
    Xue Y; Morris JL; Yang K; Fu Z; Zhu X; Johnson F; Meehan B; Witkowski L; Yasmeen A; Golenar T; Coatham M; Morin G; Monast A; Pilon V; Fiset PO; Jung S; Gonzalez AV; Camilleri-Broet S; Fu L; Postovit LM; Spicer J; Gotlieb WH; Guiot MC; Rak J; Park M; Lockwood W; Foulkes WD; Prudent J; Huang S
    Nat Commun; 2021 Sep; 12(1):5404. PubMed ID: 34518526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
    Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
    Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chromatin remodeling defects and cancer: the SWI/SNF example].
    Bourdeaut F; Bièche I
    Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SWI/SNF-Related, Matrix Associated, Actin-Dependent Regulator of Chromatin A4 Core Complex Represses Respiratory Syncytial Virus-Induced Syncytia Formation and Subepithelial Myofibroblast Transition.
    Xu X; Qiao D; Dong C; Mann M; Garofalo RP; Keles S; Brasier AR
    Front Immunol; 2021; 12():633654. PubMed ID: 33732255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.